[Recent advance in luteinizing hormone-releasing hormone analogue therapy in management of prostate cancer].
Luteinizing hormone-releasing hormone (LHRH) analogue therapy is one of the most widely used hormonal therapy for prostate cancer. LHRH analogue is effective and safety therapy for prostate cancer, when appropriate consideration is given to the disease flare. Recently, new long acting 3-month LHRH analogue depot has been developed and showed the therapeutic equivalence to the 1-month depot. In basic research, the expression of LHRH and its receptor has been demonstrated in some kinds of hormone depend cancer including prostate cancer. Although precise role of LHRH system in those cancers remains unclear, these findings suggests the presence of an autocrine system based on LHRH. More understanding of LHRH system might provide new treatment approaches to those cancer.
Kawai
K
K
Department of Urology, University of Tsukuba.
Akaza
H
H
D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy*; D011471:Prostatic Neoplasms / Q000188:drug therapy*
D018931:Antineoplastic Agents, Hormonal; D003692:Delayed-Action Preparations; D007987:Gonadotropin-Releasing Hormone